In the Claims:

This listing of claims will replace all prior versions and listing of claims in this application.

1. (currently amended) A compound of formula **(I):**



(I)

wherein

R^1 is $C_{1\text{-}10}$ alkyl, $C_{3\text{-}8}$ alkenyl, $C_{3\text{-}8}$ cycloalkyl, ($C_{3\text{-}8}$ cycloalkyl)$C_{1\text{-}6}$ alkyl, ($C_{3\text{-}8}$ cycloalkyl)$C_{3\text{-}8}$ alkenyl, or ($C_{1\text{-}8}$ alkylcarbonyl)$C_{1\text{-}8}$ alkyl;

n is 1;

X is O;

R^2 and R^3 independently are hydrogen, fluoro, chloro, bromo, nitro, trifluoromethyl, methyl, or $C_{1\text{-}3}$alkoxy;

R^4 is G

G is LQ;

L is $-CH_2-$;

Q is a saturated, un-substituted N-linked heterocyclyl, selected from the group consisting of ~~diazepanyl,~~ azepanyl, morpholinyl, ~~decahydroisoquinolin-2-yl,~~ piperidinyl and pyrrolidinyl;

~~alkyl;~~

provided however that when R^1 is methyl, G is not piperidin-1-ylmethyl; and

wherein each of the above alkyl, alkenyl, and cycloalkyl, groups may each be independently and optionally substituted with between 1 and 3 substituents independently selected from trifluoromethyl, methoxy, halo, amino, nitro, hydroxy, and C_{1-3} alkyl;

provided that when R^1 is methyl, R^2 and R^3 are both H and X is O, then R^4 is not 4-morpholin-4-ylmethyl;

or a pharmaceutically acceptable salt, ester, tautomer, ~~solvate~~ or amide thereof.

2. (original) A compound of claim 1, wherein R^1 is C_{1-10} alkyl.

3. (original) A compound of claim 1, wherein R^1 is C_{3-5} alkyl.

4. (original) A compound of claim 1, wherein wherein R^1 is isopropyl.

5-40: Cancelled

41. (original) A compound of claim 1 selected from the group consisting of:
(4-Azepan-1-ylmethyl-phenyl)-(4-*sec*-butyl-piperazin-1-yl)-methanone;
(4-Isopropyl-piperazin-1-yl)-(4-piperidin-1-ylmethyl-phenyl)-methanone;
(4-*sec*-Butyl-piperazin-1-yl)-(4-piperidin-1-ylmethyl-phenyl)-methanone;
{4-(1-Ethyl-propyl)-piperazin-1-yl}-(4-piperidin-1-ylmethyl-phenyl)-methanone;
{4-(1-Ethyl-propyl)-piperazin-1-yl}-(4-pyrrolidin-1-ylmethyl-phenyl)-methanone;
(4-Isopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone;
(4-sec-Butyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride; and
{4-(1-Ethyl-propyl)-piperazin-1-yl}-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride.

42. (original) A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically-acceptable excipient.

43. (original) A compound of claim 1 isotopically-labelled to be detectable by PET or SPECT.

Claims 44-46: Cancelled

47. (withdrawn) A method for treating a disease or condition modulated by at least one receptor selected from the histamine H_1 receptor and the histamine H_3 receptor, said method comprising (a) administering to a subject a jointly effective amount of a histamine H_1 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, said method providing a jointly therapeutically effective amount of said compounds.

48. (withdrawn) The method of claim 47 wherein the histamine H_1 receptor antagonist and the compound of claim 1 are present in the same dosage form.

49. (withdrawn) A method for treating diseases or conditions modulated by at least one receptor selected from the histamine H_2 receptor and the histamine H_3 receptor in a subject, comprising (a) administering to the subject a jointly effective amount of a histamine H_2 receptor antagonist compound, and (b) administering to the subject a jointly effective amount of a compound of claim 1, said method providing a jointly therapeutically effective amount of said compounds.

50. (withdrawn) The method of claim 39 wherein the histamine H_2 receptor antagonist and the compound of claim 1 are present in the same dosage form.

51. (original) A method for treating one or more disorders or conditions selected from the group consisting of sleep/wake disorders, narcolepsy, and arousal/vigilance disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

52. (original) A method for treating attention deficit hyperactivity disorders (ADHD), comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

53. (original) A method for treating one or more disorders or conditions selected from the group consisting of dementia, mild cognitive impairment (pre-dementia), cognitive dysfunction, schizophrenia, depression, manic disorders, bipolar disorders, and learning and memory disorders, comprising administering to a subject a therapeutically effective amount of a compound of claim 1.

54-58: Cancelled

59. (previously presented) Acompound of claim 1, wherein R^1 is C_{3-8} cycloalkyl.

60. (currently amended) A compound that is: (4-Isopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone.

61. (previously presented) A compound that is: (4-sec-Butyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride.

62. (previously presented) A compound that is: {4-(1-Ethyl-propyl)-piperazin-1-yl}-(4-morpholin-4-ylmethyl-phenyl)-methanone dihydrochloride.

63. (new) A compound that is: {4-(1-Ethyl-propyl)-piperazin-1-yl}-{4-(decahydro-isoquinolin-2-ylmethyl)-phenyl}-methanone.